Regeneron Pharmaceuticals' Other Non Operating Income rose 130.92% to $755.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 41.55%. This contributed to the annual value of $844.4 million for FY2024, which is 274.96% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Other Non Operating Income stood at $755.8 million for Q3 2025, which was up 70.69% from $442.8 million recorded in Q2 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income peaked at $755.8 million during Q3 2025, and registered a low of -$183.8 million during Q1 2022.
Its 3-year average for Other Non Operating Income is $235.5 million, with a median of $193.0 million in 2023.
In the last 5 years, Regeneron Pharmaceuticals' Other Non Operating Income crashed by 268.78% in 2021 and then surged by 1,937.80% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income (Quarterly) stood at -$122.2 million in 2021, then spiked by 259.82% to $195.3 million in 2022, then dropped by 1.18% to $193.0 million in 2023, then slumped by 111.19% to -$21.6 million in 2024, then soared by 130.92% to $755.8 million in 2025.
Its Other Non Operating Income was $755.8 million in Q3 2025, compared to $442.8 million in Q2 2025 and $322.0 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value